Advances in Melanoma Immunotherapy
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 3008
Special Issue Editor
Special Issue Information
Dear Colleagues,
The field of melanoma treatment is witnessing revolutionary advancements, particularly in the field of immunotherapy. This special issue aims to encapsulate these groundbreaking changes by gathering cutting-edge research focused on the mechanisms, efficacy, and future directions of immunotherapies and other new therapies against metastatic melanoma. We invite contributions that explore novel therapeutic targets and immune response modulation. Our goal is to provide a comprehensive overview that will inform and inspire ongoing and future efforts in combating melanoma through immunological approaches.
Dr. Jeffrey D. McBride
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma immunotherapy
- therapeutic targets
- immune modulation
- oncolytic viruses
- checkpoint inhibitors
- cancer vaccines
- tumor biomarkers
- tumor microenvironment
- treatment strategies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
